Autologous hematopoietic stem cell transplantation in autoimmune diseases

Expert Review of Hematology

Volumn 2, Issue 6, 2009, Pages 699-715

  Annaloro, Claudio ^a   Onida, Francesco ^a   Lambertenghi Deliliers, Giorgio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Autoimmune diseases; Autologous hematopoietic stem cell transplantation; Graft manipulation; Immune reconstitution; Quality of life; Stem cell harvesting; Transplant related mortality

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; THYMOCYTE ANTIBODY;

AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CROHN DISEASE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKEMIA; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MULTIPLE SCLEROSIS; RATS; REMISSION INDUCTION; SCLERODERMA, SYSTEMIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 77953397831     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.60     Document Type: Review

References (178)

1. Alderuccio F, Siatskas C, Chan J et al.. Haematopoietic stem cell gene therapy to treat autoimmune disease. Curr. Stem Cell Res. Ther. 1(3), 279-287 (2006).
2. Brodsky RA, Smith BD. Bone marrow transplantation for autoimmune diseases. Curr. Opin. Oncol. 11(2), 83-86 (1999).
3. Marmont AM. New horizons in the treatment of autoimmune diseases: immunoablation and stem cell transplantation. Annu. Rev. Med. 51, 115-134 (2000).
4. Marmont AM. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems. Haematologica 86(4), 337-345 (2001).
5. Marmont AM. Will hematopoietic stem cell transplantation cure human autoimmune diseases? J. Autoimmun. 30(3), 145-150 (2008).
6. Siatskas C, Chan J, Field J et al.. Gene therapy strategies towards immune tolerance to treat the autoimmune diseases. Curr. Gene Ther. 6(1), 45-58 (2006).
7. Marmont AM, Gualandi F, van Lint MT, Guastoni C, Bacigalupo A. Long term complete remission of severe nephrotic syndrome secondary to diffuse global (IV-G) lupus nephritis following autologous, haematopoietic peripheral stem (CD34+) cell transplantation. Lupus 15(1), 44-46 (2006).
8. Gratwohl A, Passweg J, Bocelli-Tyndall C et al.. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 35(9), 869-879 (2005). (Pubitemid 40667629)
9. Tyndall A, Daikeler T. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Acta Haematol. 114(4), 239-247 (2005). (Pubitemid 41567007)
10. Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br. J. Haematol. 128(4), 432-459 (2005).
11. Sullivan KM, Parkman R, Walters MC. Bone marrow transplantation for nonmalignant disease. Hematol. Am. Soc. Hematol. Educ. Program. 319-338 (2000).
12. Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br. J. Haematol. 126(5), 637-649 (2004).
13. Denman AM, Russell AS, Denman EJ. Adoptive transfer of the diseases of New Zealand black mice to normal mouse strains. Clin. Exp. Immunol. 5(6), 567-595 (1969).
14. Morton JI, Siegel BV. Transplantation of autoimmune potential. I. Development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand Black mice. Proc. Natl Acad. Sci. USA 71(6), 2162-2165 (1974).
15. Ikehara S, Good RA, Nakamura T et al.. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc. Natl Acad. Sci. USA 82(8), 2483-2487 (1985).
16. Morton JI, Siegel BV. Transplantation of autoimmune potential. IV. Reversal of the NZB autoimmune syndrome by bone marrow transplantation. Transplantation 27(2), 133-134 (1979).
17. Van Bekkum DW, Bohre EP, Houben PF, Knaan-Shanzer S. Regression of adjuvantinduced arthritis in rats following bone marrow transplantation. Proc. Natl Acad. Sci. USA 86(24), 10090-10094 (1989).
18. Karussis DM, Slavin S, Lehmann D, Mizrachi-Koll R, Abramsky O, Ben-Nun A. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J. Immunol. 148(6), 1693-1698 (1992).
19. Van Gelder M, Kinwel-Bohre EP, Van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant. 11(3), 233-241 (1993).
20. Ikehara S. Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment (review). Int. J. Mol. Med. 1(1), 5-16 (1998).
21. Van Bekkum DW. Experimental basis for the treatment of autoimmune diseases with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 32(Suppl. 1), S37-S39 (2003).
22. Hahn BH. The potential role of autologous stem cell transplantation in patients with systemic lupus erythematosus. J. Rheumatol. Suppl. 48, 89-93 (1997).
23. Marmont AM. Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica 83(8), 733-743 (1998).
24. Burt RK, Verda L, Oyama Y, Statkute L, Slavin S. Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin. Immunopathol. 26(1-2), 57-69 (2004).
25. Porta C, Caporali R, Epis O et al.. Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidated to autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 33(7), 721-728 (2004).
26. Ikehara S. A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases. J. Autoimmun. 30(3), 108-115 (2008).
27. Ikehara S, Kawamura M, Takao F et al.. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. Proc. Natl Acad. Sci. USA 87(21), 8341-8344 (1990).
28. Rosler W, Manger B, Repp R, Kalden JR, Gramatzki M. Autologous PBPCT in a patient with lymphoma and Sjogren's syndrome: complete remission of lymphoma without control of the autoimmune disease. Bone Marrow Transplant. 22(2), 211-213 (1998).
29. Schachna L, Ryan PF, Schwarer AP. Malignancy-associated remission of systemic lupus erythematosus maintained by autologous peripheral blood stem cell transplantation. Arthritis Rheum. 41(12), 2271-2272 (1998).
30. Burt RK, Traynor AE, Craig R, Marmont AM. The promise of hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 31(7), 521-524 (2003). (Pubitemid 36546828)
31. Mudad R, Hussein A, Peters WP. Guillain-Barre syndrome following autologous bone marrow transplantation. Am. J. Clin. Oncol. 18(2), 167-169 (1995).
32. Karthaus M, Gabrysiak T, Brabant G et al.. Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells. Bone Marrow Transplant. 20(8), 697-699 (1997).
33. Ishikawa F, Shigematsu H, Gondo H, Okamura T, Niho Y. Autoreactive antibodies following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 22(7), 729-731 (1998). (Pubitemid 28486376)
34. Tsuchiyama J, Imajo K, Sakaguchi N et al.. Recurrent idiopathic iridocyclitis after autologous peripheral blood stem-cell transplantation followed by G-CSF administration for acute lymphoblastic leukemia. Ann. Hematol. 79(5), 269-271 (2000).
35. Isshiki I, Okamoto S, Kakimoto T et al.. Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma. Int. J. Hematol. 84(4), 354-358 (2006).
36. Zhang L, Arrington S, Keung YK. Guillain-Barre syndrome after transplantation. Leuk. Lymphoma 49(2), 291-297 (2008).
37. Bohgaki T, Atsumi T, Koike T. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun. Rev. 7(3), 198-203 (2008).
38. Kline J, Subbiah S, Lazarus HM, van Besien K. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant. 41(6), 505-513 (2008).
39. Lambertenghi-Deliliers GL, Annaloro C, Della Volpe A, Oriani A, Pozzoli E, Soligo D. Multiple autoimmune events after autologous bone marrow transplantation. Bone Marrow Transplant. 19(7), 745-747 (1997). (Pubitemid 27182500)
40. Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract. Res. Clin. Haematol. 20(2), 349-360 (2007).
41. Burt RK, Traynor A, Statkute L et al.. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295(5), 527-535 (2006).
42. Sun W, Popat U, Hutton G et al.. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 127(Pt 5), 996-1008 (2004).
43. Isaacs JD, Thiel A. Stem cell transplantation for autoimmune disorders. Immune reconstitution. Best Pract. Res. Clin. Haematol. 17(2), 345-358 (2004).
44. Muraro PA, Douek DC, Packer A et al.. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 201(5), 805-816 (2005).
45. Thiel A, Alexander T, Schmidt CA et al.. Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol. 119(1), 22-27 (2008).
46. Vonk MC, Marjanovic Z, van den Hoogen FH et al.. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann. Rheum. Dis. 67(1), 98-104 (2008).
47. McSweeney PA, Nash RA, Sullivan KM et al.. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100(5), 1602-1610 (2002).
48. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp. Hematol. 28(7), 853-857 (2000).
49. Fassas A, Kazis A. High-dose immunosuppression and autologous hematopoietic stem cell rescue for severe multiple sclerosis. J. Hematother. Stem Cell Res. 12(6), 701-711 (2003). (Pubitemid 38101559)
50. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Int. J. Hematol. 76(Suppl. 1), 226-247 (2002).
51. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 99(3), 768-784 (2002).
52. Herrmann MM, Gaertner S, Stadelmann C et al.. Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood 106(5), 1875-1883 (2005).
53. Muraro PA, Douek DC. Renewing the T cell repertoire to arrest autoimmune aggression. Trends Immunol. 27(2), 61-67 (2006).
54. van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatol. (Oxford) 45(10), 1187-1193 (2006).
55. de Kleer I, Vastert B, Klein M et al.. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 107(4), 1696-1702 (2006).
56. Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, Bishop MR. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant. 29(8), 709-710 (2002).
57. De Buys P, Khanna D, Furst DE. Hemopoietic stem cell transplantation in rheumatic diseases - an update. Autoimmun. Rev. 4(7), 442-449 (2005).
58. Tyndall A. Autologous hematopoietic stem cell transplantation for severe autoimmune disease with special reference to rheumatoid arthritis. J. Rheumatol. Suppl. 64, 5-7 (2001). (Pubitemid 32951778)
59. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M et al.. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 37(5), 439-449 (2006).
60. Passweg J, Tyndall A. Autologous stem cell transplantation in autoimmune diseases. Semin. Hematol. 44(4), 278-285 (2007).
61. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11), 1444-1452 (1983).
62. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35(6), 630-640 (1992).
63. Clements PJ. Measuring disease activity and severity in scleroderma. Curr. Opin. Rheumatol. 7(6), 517-521 (1995).
64. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70(3), 439-444 (1976).
65. Openshaw H, Nash RA, McSweeney PA. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. Biol. Blood Marrow Transplant. 8(5), 233-248 (2002).
66. Su L, Xu J, Ji BX et al.. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int. J. Hematol. 84(3), 276-281 (2006).
67. Statkute L, Verda L, Oyama Y et al.. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 39(6), 317-329 (2007).
68. Holmberg LA, Boeckh M, Hooper H et al.. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94(12), 4029-4035 (1999).
69. Nash RA, Bowen JD, McSweeney PA et al.. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102(7), 2364-2372 (2003).
70. Nash RA, Dansey R, Storek J et al.. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol. Blood Marrow Transplant. 9(9), 583-591 (2003).
71. Miniati I, Matucci Cerinic M. Pulmonary fibrosis in systemic sclerosis: is treatment with cyclophosphamide more effective than placebo? Nat. Clin. Pract. Rheumatol. 3(7), 372-373 (2007).
72. Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin. Biol. Ther. 3(7), 1041-1049 (2003).
73. Farge D, Marolleau JP, Zohar S et al.. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre Phase I-II study. Br. J. Haematol. 119(3), 726-739 (2002).
74. Farge D, Passweg J, van Laar JM et al.. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann. Rheum. Dis. 63(8), 974-981 (2004).
75. Tyndall A, Fassas A, Passweg J et al.. Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality. Autoimmune disease and lymphoma working parties of the European group for blood and marrow transplantation, the European league against rheumatism and the international stem cell project for autoimmune disease. Bone Marrow Transplant. 24(7), 729-734 (1999).
76. Binks M, Passweg JR, Furst D et al.. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann. Rheum. Dis. 60(6), 577-584 (2001).
77. Miniati I, Conforti ML, Bernardo P, Tyndall A, Gensini GF, Matucci-Cerinic M. Hematopoietic stem cell transplantation in autoimmune diseases: algorithm for cardiovascular assessment. Herz 32(1), 43-50 (2007).
78. Saccardi R, Tyndall A, Coghlan G et al.. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant. 34(10), 877-881 (2004).
79. Burt RK, Patel D, Thomas J et al.. The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis. Bone Marrow Transplant. 34(9), 745-751 (2004).
80. Tsukamoto H, Nagafuji K, Horiuchi T et al.. A Phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann. Rheum. Dis. 65(4), 508-514 (2006).
81. Weaver CH, Schwartzberg LS, Hainsworth J et al.. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant. 19(7), 671-678 (1997). (Pubitemid 27182489)
82. Fleming JN, Nash RA, McLeod DO et al.. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3(1), e1452 (2008).
83. Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res. Ther. 9(2), 206 (2007).
84. van Laar JM, Tyndall A. Cellular therapy of systemic sclerosis. Curr. Rheumatol. Rep. 10(3), 189-194 (2008).
85. Larghero J, Farge D, Braccini A et al.. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann. Rheum. Dis. 67(4), 443-449 (2008).
86. Fassas A, Kimiskidis VK. Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience. J. Neurol. Sci. 223(1), 53-58 (2004). (Pubitemid 38903262)
87. Hutchinson M, Kappos L, Calabresi PA et al.. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J. Neurol. 256(3), 405-415 (2009).
88. Havrdova E, Galetta S, Hutchinson M et al.. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 8(3), 254-260 (2009).
89. Carson KR, Focosi D, Major EO et al.. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol. 10(8), 816-824 (2009).
90. Daumer M, Griffith LM, Meister W, Nash RA, Wolinsky JS. Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation. Mult. Scler. 12(2), 174-179 (2006).
91. Roccatagliata L, Rocca M, Valsasina P et al.. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult. Scler. 13(8), 1068-1070 (2007).
92. Saccardi R, Kozak T, Bocelli-Tyndall C et al.. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult. Scler. 12(6), 814-823 (2006).
93. Capello E, Saccardi R, Murialdo A et al.. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurol. Sci. 26(Suppl. 4), S200-203 (2005). (Pubitemid 43085211)
94. Gualandi F, Bruno B, Van Lint MT et al.. Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. Ann. NY Acad. Sci. 1110, 455-464 (2007).
95. Shevchenko YL, Novik AA, Kuznetsov AN et al.. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp. Hematol. 36(8), 922-928 (2008).
96. Saccardi R, Mancardi GL, Solari A et al.. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105(6), 2601-2607 (2005).
97. Snir O, Lavie G, Achiron A et al.. G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: a possible mechanism for exacerbation of multiple sclerosis. J. Neuroimmunol. 172(1-2), 145-155 (2006).
98. Burt RK, Loh Y, Cohen B et al.. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a Phase I/II study. Lancet Neurol. 8(3), 244-253 (2009).
99. Mancardi GL, Saccardi R, Filippi M et al.. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57(1), 62-68 (2001).
100. Healey KM, Pavletic SZ, Al-Omaishi J et al.. Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation. Mult. Scler. 10(3), 284-289 (2004).
101. Karussis D, Slavin S. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures. J. Neurol. Sci. 223(1), 59-64 (2004).
102. Metz I, Lucchinetti CF, Openshaw H et al.. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130(Pt 5), 1254-1262 (2007).
103. Inglese M, Mancardi GL, Pagani E et al.. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J. Neurol. Neurosurg. Psychiatry 75(4), 643-644 (2004).
104. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66(12), 1935-1937 (2006).
105. Rocca MA, Mondria T, Valsasina P et al.. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am. J. Neuroradiol. 28(9), 1659-1661 (2007).
106. Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin. Transplant. 20(4), 485-489 (2006).
107. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 7(7), 626-636 (2008).
108. Blanco Y, Saiz A, Carreras E, Graus F. Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis. J. Neuroimmunol. 153(1-2), 190-194 (2004).
109. Drachman DB, Brodsky RA. High-dose therapy for autoimmune neurologic diseases. Curr. Opin. Oncol. 17(2), 83-88 (2005).
110. Silani V, Cova L. Stem cell transplantation in multiple sclerosis: safety and ethics. J. Neurol. Sci. 265(1-2), 116-121 (2008).
111. Craig RM. Autologous hematopoietic stem cell transplantation for Crohn's disease. Autoimmun. Rev. 1(4), 244-249 (2002).
112. Cassinotti A, Annaloro C, Ardizzone S et al.. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 57(2), 211-217 (2008).
113. Leung Y, Geddes M, Storek J, Panaccione R, Beck PL. Hematopoietic cell transplantation for Crohn's disease; is it time? World J. Gastroenterol. 12(41), 6665-6673 (2006).
114. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment. Pharmacol. Ther. 25(8), 861-870 (2007).
115. Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment. Pharmacol. Ther. 23(3), 377-385 (2006).
116. Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, Scalone R. Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant. Bone Marrow Transplant. 26(8), 921-923 (2000).
117. Craig RM, Traynor A, Oyama Y, Burt RK. Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplant. 32(Suppl. 1), S57-S59 (2003). (Pubitemid 37069513)
118. Oyama Y, Craig RM, Traynor AE et al.. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128(3), 552-563 (2005).
119. Barkholt L, Lofberg R. Resetting the immune system in refractory Crohn's disease: is autologous hematopoietic stem cell transplantation the way forward? Gastroenterology 128(3), 786-789 (2005).
120. Onida FAC, Cassinotti A, Della Volpe A et al.. Autologous haematopoietic unselected peripheral blood stem cell transplantation in refractory Crohn's disease: up to 2-years follow-up of a Phase I-II trial. Bone Marrow Tranplant. 41(S1), S135 abs (2008).
121. Snowden JA, Biggs JC, Milliken ST, Fuller A, Brooks PM. A Phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum. 42(11), 2286-2292 (1999).
122. Teng YK, Verburg RJ, Verpoort KN et al.. Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study. Arthritis. Res. Ther. 9(5), R106 (2007).
123. Snowden JA, Passweg J, Moore JJ et al.. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J. Rheumatol. 31(3), 482-488 (2004).
124. Teng YK, Verburg RJ, Sont JK, Van Den Hout WB, Breedveld FC, Van Laar JM. Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. Arthritis Rheum. 52(8), 2272-2276 (2005).
125. Bingham SJ, Snowden J, McGonagle D et al.. Autologous stem cell transplantation for rheumatoid arthritis - interim report of 6 patients. J. Rheumatol. Suppl. 64, 21-24 (2001).
126. Verburg RJ, Toes RE, Fibbe WE, Breedveld FC, van Laar JM. High dose chemotherapy and autologous hematopoietic stem cell transplantation for rheumatoid arthritis: a review. Hum. Immunol. 63(8), 627-637 (2002).
127. Daikeler T, Kotter I, Bocelli Tyndall C et al.. Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Ann. Rheum. Dis. 66(2), 202-207 (2007).
128. Bingham SJ, Moore JJ. Stem cell transplantation for autoimmune disorders. Rheumatoid arthritis. Best Pract. Res. Clin. Haematol. 17(2), 263-276 (2004).
129. Tyndall A, Koike T. High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future direction. Intern. Med. 41(8), 608-612 (2002).
130. Verburg RJ, Sont JK, Vliet Vlieland TP et al.. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis. J. Rheumatol. 28(4), 719-727 (2001).
131. Jayne D, Tyndall A. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13(5), 359-365 (2004). (Pubitemid 38788497)
132. Lehnhardt FG, Scheid C, Holtik U et al.. Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction. Lupus 15(4), 240-243 (2006).
133. Papadaki HA, Boumpas DT, Gibson FM et al.. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br. J. Haematol. 115(1), 167-174 (2001).
134. Lisukov IA, Sizikova SA, Kulagin AD et al.. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 13(2), 89-94 (2004).
135. Loh Y, Oyama Y, Statkute L et al.. Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus patients with cardiac dysfunction: feasibility and reversibility of ventricular and valvular dysfunction with transplant-induced remission. Bone Marrow Transplant. 40(1), 47-53 (2007).
136. Statkute L, Traynor A, Oyama Y et al.. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 106(8), 2700-2709 (2005).
137. Alexander T, Thiel A, Rosen O et al.. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113(1), 214-223 (2009).
138. Marmont AM, van Lint MT, Gualandi F, Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 6(6), 545-548 (1997).
139. Musso M, Porretto F, Crescimanno A et al.. Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus 7(7), 492-494 (1998).
140. Traynor A, Burt RK. Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Rheumatology (Oxford), 38(8), 767-772 (1999).
141. Fouillard L, Gorin NC, Laporte JP, Leon A, Brantus JF, Miossec P. Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood. Lupus 8(4), 320-323 (1999).
142. Trysberg E, Lindgren I, Tarkowski A. Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus. Ann. Rheum. Dis. 59(3), 236-238 (2000).
143. Brunner M, Greinix HT, Redlich K et al.. Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report. Arthritis Rheum. 46(6), 1580-1584 (2002).
144. Talaulikar D, Tymms KE, Prosser I, Smith R. Autologous peripheral blood stem cell transplantation with in vivo T-cell depletion for life threatening refractory systemic lupus erythematosus. Lupus 14(2), 159-163 (2005).
145. Traynor AE, Schroeder J, Rosa RM et al.. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a Phase I study. Lancet 356(9231), 701-707 (2000).
146. Traynor AE, Barr WG, Rosa RM et al.. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum. 46(11), 2917-2923 (2002).
147. Illei GG, Pavletic SZ. Blood stem cells as therapy for severe lupus. Expert Opin. Biol. Ther. 5(9), 1153-1164 (2005).
148. Klumpp TR, Herman JH, Macdonald JS, Schnell MK, Mullaney M, Mangan KF. Autoimmune neutropenia following peripheral blood stem cell transplantation. Am. J. Hematol. 41(3), 215-217 (1992).
149. Ashihara E, Shimazaki C, Hirata T et al.. Autoimmune thrombocytopenia following peripheral blood stem cell autografting. Bone Marrow Transplant. 12(3), 297-299 (1993).
150. Lambertenghi Deliliers G, Annaloro C, Pozzoli E et al. Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation. Leuk. Res. 23(3), 291-297 (1999).
151. Jillella AP, Kallab AM, Kutlar A. Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options. Bone Marrow Transplant. 26(8), 925-927 (2000).
152. Hequet O, Salles G, Ketterer N et al. Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant. 32(1), 89-95 (2003).
153. Loh Y, Oyama Y, Statkute L et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 109(6), 2643-12548 (2007).
154. Fogarty PF, Dunbar CE. Resetting the immune system in immune thrombocytopenic purpura: immunoablative strategies. Clin. Adv. Hematol. Oncol. 1(6), 365-371 (2003).
155. Passweg JR. Haematopoietic stem cell transplantation for immune thrombopenia and other refractory autoimmune cytopenias. Best Pract. Res. Clin. Haematol. 17(2), 305-315 (2004).
156. Skoda RC, Tichelli A, Tyndall A, Hoffmann T, Gillessen S, Gratwohl A.
157. Seeliger S, Baumann M, Mohr M, Jurgens H, Frosch M, Vormoor J. Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. Eur. J. Pediatr. 160(8), 492-496 (2001).
158. Wulffraat NM, de Kleer IM, Prakken BJ, Kuis W. Stem cell transplantation for autoimmune disorders. Refractory juvenile idiopathic arthritis. Best Pract. Res. Clin. Haematol. 17(2), 277-289 (2004).
159. Brinkman DM, de Kleer IM, ten Cate R et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum. 56(7), 2410-2421 (2007).
160. Wulffraat NM, Haas PJ, Frosch M et al. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann. Rheum. Dis. 62(3), 236-241 (2003).
161. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 42(2), 375-379 (2003).
162. Sreedharan A, Bowyer S, Wallace CA et al. Macrophage activation syndrome and other systemic inflammatory conditions after BMT. Bone Marrow Transplant. 37(7), 629-634 (2006).
163. Al-toma A, Visser OJ, van Roessel HM et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 109(5), 2243-2249 (2007).
164. Oryoji K, Himeji D, Nagafuji K et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin. Rheumatol. 24(6), 637-640 (2005).
165. Voltarelli JC, Couri CE, Stracieri AB Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA 297(14), 1568-1576 (2007).
166. Fousteri G, Hayek A, von Herrath M. Stopping diabetes in its tracks: autologous non-myeloablative stem cell transplantation. Regen. Med. 2(5), 845-851 (2007).
167. Kyriakou DS, Alexandrakis MG, Zachou K, Passam F, Stathakis NE, Dalekos GN. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis Type 1 and primary biliary cirrhosis. J. Hepatol. 39(5), 679-685 (2003).
168. Lanza F, Dominici M, Govoni M et al. Prolonged remission state of refractory adult onset Still's disease following CD34-selected autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 25(12), 1307-1310 (2000).
169. Marmont AM. Introduction. Autoimmunity 41(8), 556-562 (2008).
170. Lambertenghi Deliliers G, Annaloro C, Lambertenghi Deliliers D. Complications of autologous hematopoietic stem cell transplantation. Haematologia (Budap.) 30(4), 253-262 (2000).
171. Brenner MK. Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential. Best Pract. Res. Clin. Haematol. 17(2), 359-374 (2004).
172. Blanco Y, Saiz A, Carreras E, Graus F. Autologous haematopoietic-stem- cell transplantation for multiple sclerosis. Lancet Neurol. 4(1), 54-63 (2005).
173. Saccardi R, Gualandi F. Hematopoietic stem cell transplantation procedures. Autoimmunity 41(8), 520-526 (2008).
174. Uccelli A, Mancardi G, Chiesa S. Is there a role for mesenchymal stem cells in autoimmune diseases? Autoimmunity 41(8), 592-595 (2008).
175. Brodsky RA, Jones RJ. Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages. Autoimmunity 41(8), 596-600 (2008).
176. LaFace DM, Peck AB. Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetesnonsusceptible mice associated with transfer and prevention of autoimmune diabetes. Diabetes 38(7), 894-901 (1989).
177. Ende N, Czarneski J, Raveche E. Effect of human cord blood transfer on survival and disease activity in MRL-lpr/lpr mice. Clin. Immunol. Immunopathol. 75(2), 190-195 (1995).
178. Smith-Berdan S, Gille D, Weissman IL, Christensen JL. Reversal of autoimmune disease in lupus-prone New Zealand black/ New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells. Blood 110(4), 1370-1378 (2007).